arXiv subjects

Hsien-Da Huang

Publications and source records attributed to Hsien-Da Huang.

3 recordsLinked to original sources

arXiv2026

MIRCID: Inferred Hub-miRNAs Drive Cross-Task Improvements in Drug Mechanistic Modeling

Drug mechanism-of-action (MoA) modeling commonly relies on perturbational transcriptomes, but matched microRNA (miRNA) measurements are often unavailable. Inferred regulatory features offer a scalable way to reuse these data. Here, we present MIRCID, a framework comparing gene expression with inferred transcription factor (TF) activity and miRNA expression across pathway classification and similarity-based MoA retrieval. HubmiRNet infers 414 pan-cancer hub miRNAs (HubmiRs) from 977 L1000 landmark genes, achieving a Pearson correlation coefficient of 87.72%; its 1,298-output variant also outperformed SiCmiR on the full-miRNA task (71.21% versus 67.30%). In the evaluated comparisons, miRNA augmentation provided more consistent gains than TF activity. Generic embedding controls showed model-dependent utility, while complementarity analyses identified a distinct, partially linearly recoverable representation that retained gene-derived structure. Illustrative rescue cases linked improved classification to biologically plausible miRNA patterns in samples with weak transcriptional signatures. These findings support inferred HubmiRs as a biologically informed recoding of transcriptomic data for perturbational drug modeling, while leaving recovery of measured perturbational miRNA responses to further validation.

cs.LG↗

arXiv2025

SiCmiR Atlas: Single-Cell miRNA Landscapes Reveals Hub-miRNA and Network Signatures in Human Cancers

microRNA are pivotal post-transcriptional regulators whose single-cell behavior has remained largely inaccessible owing to technical barriers in single-cell small-RNA profiling. We present SiCmiR, a two-layer neural network that predicts miRNA expression profile from only 977 LINCS L1000 landmark genes reducing sensitivity to dropout of single-cell RNA-seq data. Proof-of-concept analyses illustrate how SiCmiR can uncover candidate hub-miRNAs in bulk-seq cell lines and hepatocellular carcinoma, scRNA-seq pancreatic ductal carcinoma and ACTH-secreting pituitary adenoma and extracellular-vesicle-mediated crosstalk in glioblastoma. Trained on 6462 TCGA paired miRNA-mRNA samples, SiCmiR attains state-of-the-art accuracy on held-out cancers and generalizes to unseen cancer types, drug perturbations and scRNA-seq. We next constructed SiCmiR-Atlas, containing 632 public datasets, 9.36 million cells, 726 cell types, which is the first dedicated database of single-cell mature miRNA expression--providing interactive visualization, biomarker identification and cell-type-resolved miRNA-target networks. SiCmiR transforms bulk-derived statistical power into a single-cell view of miRNA biology and provides a community resource SiCmiR Atlas for biomarker discovery. SiCmiR Atlas is avilable at https://awi.cuhk.edu.cn/~SiCmiR/.

q-bio.GN↗

arXiv2025

SCOPE-DTI: Semi-Inductive Dataset Construction and Framework Optimization for Practical Usability Enhancement in Deep Learning-Based Drug Target Interaction Prediction

Deep learning-based drug-target interaction (DTI) prediction methods have demonstrated strong performance; however, real-world applicability remains constrained by limited data diversity and modeling complexity. To address these challenges, we propose SCOPE-DTI, a unified framework combining a large-scale, balanced semi-inductive human DTI dataset with advanced deep learning modeling. Constructed from 13 public repositories, the SCOPE dataset expands data volume by up to 100-fold compared to common benchmarks such as the Human dataset. The SCOPE model integrates three-dimensional protein and compound representations, graph neural networks, and bilinear attention mechanisms to effectively capture cross domain interaction patterns, significantly outperforming state-of-the-art methods across various DTI prediction tasks. Additionally, SCOPE-DTI provides a user-friendly interface and database. We further validate its effectiveness by experimentally identifying anticancer targets of Ginsenoside Rh1. By offering comprehensive data, advanced modeling, and accessible tools, SCOPE-DTI accelerates drug discovery research.

cs.LG↗